Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Files An 8-K Other EventsItem 8.01 Other Events.
On June1, 2018, Agios Pharmaceuticals, Inc. (the “Company”) issued a press release announcing clinical data from the Company’s Phase 1 study evaluating single agent AG-881 in patients with isocitrate dehydrogenase (“IDH”) mutant-positive advanced glioma and other solid tumors. On June2, 2018, the Company issued a press release announcing updated clinical data from the Company’s phase 1 dose-escalation and expansion trial of ivosidenib in patients with relapsed or refractory acute myeloid leukemia (“AML”) and an IDH1 mutation. On June4, 2018, the Company issued a press release announcing new data from the ongoing phase 1/2 trial of enasidenib or ivosidenib in combination with azacitadine in patients with newly diagnosed AML with an IDH2 or IDH1 mutation ineligible for intensive chemotherapy. The Company presented these data at the American Society of Clinical Oncology (ASCO) Annual Meeting held June 1-5, 2018 in Chicago, Illinois. The full text of the press releases issued in connection with these announcements are attached as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 to this Current Report on Form 8-K and incorporated herein by reference.
Item 8.01 Financial Statements and Exhibits.
AGIOS PHARMACEUTICALS INC ExhibitEX-99.1 2 d565101dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Agios Presents Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma and Other Solid Tumors – Favorable Safety Profile at Dose Levels Below 100 mg; 10 mg and 50 mg Doses Under Evaluation in Recently Initiated Glioma Perioperative Study – – Evidence of Prolonged Disease Control Observed in Non-Enhancing Glioma Population with a Median Treatment Duration of 12 Months – CHICAGO,…To view the full exhibit click
About Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. The lead product candidate in its RGD programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Its AG-221 is an orally available, selective, inhibitor of the mutated IDH2 protein indicated for the treatment of patients with cancers. Its AG-120 is an orally available, selective, inhibitor of the mutated isocitrate dehydrogenase (IDH1) protein for the treatment of patients with cancers. AG-881 is an orally available, selective, brain-penetrant, pan-IDH mutant inhibitor.